Propentofylline in the treatment of vascular dementia and Alzheimer-type dementia: Overview of phase I and phase II clinical trials

Alzheimer Disease and Associated Disorders

Volumn 12, Issue SUPPL. 2, 1998, Pages

  Mielke, Rüdiger ^a   Möller, Hans Jürgen ^b   Erkinjuntti, Timo ^c   Rosenkranz, Bernd ^d   Rother, Matthias ^d   Kittner, Barbara ^d  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Germany   (Germany)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d SANOFI   (France)

Author keywords

Alzheimer disease; Dementia; Microglia; Neuroprotection; Positron emission tomography; Propentofylline; Vascular dementia

Indexed keywords

CYTOKINE; FREE RADICAL; GLUCOSE; GLUTAMIC ACID; NERVE GROWTH FACTOR; PROPENTOFYLLINE; XANTHINE DERIVATIVE;

AGED; ALZHEIMER DISEASE; ASTROCYTE; CELL ACTIVATION; CELL LOSS; CHOLINERGIC NERVE CELL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; GLUCOSE METABOLISM; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MICROGLIA; MULTIINFARCT DEMENTIA; NEUROPROTECTION; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERBAL MEMORY;

EID: 0344197596     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (21)

1. Banati RB, Gehrmann J, Schubert P, Kreutzberg GW. Cytotoxicity of microglia. Glia 1993;7:111-8.
2. Becquemont L, Ragueneau I, Le Bot MA, et al. Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans. Clin Pharmacol Ther 1997;61:619-27.
3. Choi DW. Methods for antagonizing glutamate neurotoxicity. Cerebrovasc Brain Metab Rev 1990;2:105-47.
4. Damasio AR. Alzheimer's disease and related dementias. In: Bennett JC, Plum F, eds. Cecil textbook of medicine. Philadelphia: WB Saunders, 1996;1992-6.
5. Diagnostic and statistical manual of mental disorders. 3rd rev. ed. DSM-III-R. Washington, DC: American Psychiatric Association, 1987:97-126.
6. Fuji K, Kiramatsu M, Kameyama T, Nabeshima T. Effects of repeated administration of propentofylline on memory impairment produced by basal forebrain lesion in rats. Eur J Pharmacol 1993;236:411-7.
7. Goto M, Demura N, Sakaguchi T. Effects of propentofylline on disorder of learning and memory in rodents. Jpn J Pharmacol 1987;45: 373-378.
8. Hoechst Marion Roussell, data on file; Bridgewater, NJ.
9. Huber M, Kittner B, Hojer C, Fink GR, Neveling M, Heiss WD. Effect of propentofylline on regional cerebral glucose metabolism in acute ischemic stroke. J Cereb Blood Flow Metab 1993;13:526-30.
10. Kittner B, Rössner M, Rother M. Clinical trials in dementia with propentofylline. Ann NY Acad Sci 1997;826:307-16.
11. Mielke R, Ghaemi M, Kessler J, et al. Propentofylline enhances cerebral metabolic response to auditory stimulation in Alzheimer's disease. J Neurol Sci 1998;154:76-82.
12. Mielke R, Kittner B, Ghaemi M, et al. Propentofylline improves regional cerebral glucose metabolism and neuropsychologic performance in vascular dementia. J Neurol Sci 1996;141:59-64.
13. Möller HJ, Maurer I, Saletu B. Placebo-controlled trial of the xanthine derivative propentofylline in dementia. Pharmacopysychiatry 1994;27:159-65.
14. Nabeshima T, Nitta A, Hasegawa T. Impairment of learning and memory and the accessory symptom in aged rat as senile dementia model (3): oral administration of propentofylline produces recovery of reduced NGF content in the brain of aged rats. Jpn J Psychopharmacol 1993;13:89-95.
15. Rudolphi KA, Park CK, Rother M. Propentofylline (HWA 285) - a neuroprotective glial cell modulator: pharmacologic profile. CNS Drug Rev [in press].
16. Rudolphi KA, Schubert P, Parkinson FE, Fredholm BB. Adenosine and brain ischemia. Cerebrovasc Brain Metab Rev 1992;4:346-69.
17. Saletu B, Möller HJ, Grünberger J, et al. Propentofylline in adult-onset cognitive disorders: double-blind, placebo-controlled, clinical, psychometric and brain mapping studies. Neuropsychobiology 1990; 24:173-84.
18. Shinoda I, Furukawa Y, Furukawa S. Stimulation of nerve growth factor synthesis/secretion by propentofylline in cultured mouse astroglial cells. Biochem Pharmacol 1990;39:1813-6.
19. Si QS, Nakamura Y, Schubert P, et al. Propentofylline, a xanthine derivative, inhibits proliferation of microglia in culture. Exp Neurol 1996;137:345-9.
20. Siesjö BK. Pathophysiology and treatment of focal brain ischemia. Part II. Mechanism of damage and treatment. J Neurosurg 1992;7:337-54.
21. Yamada Y, Nakamura H, Okada Y. Propentofylline enhances the formation of long-term potentiation in guinea pig hippocampal slices. Neurosci Lett 1994;176:189-92.